UPDATE: SVB Leerink On Elevation Oncology Outperform Initiation: Firm Sees Seribantumab Potential To Be A 'Best-In-Class Asset For NRG1 Fusion Protein-Positive'; Notes Pipeline Expansion Plans In Precision Oncology & Partnership With Caris Life Sciences